Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
Harvard Business School
Boehringer Ingelheim
Medtronic

Last Updated: May 26, 2022

AVYCAZ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

DrugPatentWatch® Generic Entry Outlook for Avycaz

Avycaz was eligible for patent challenges on February 25, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 15, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for AVYCAZ
Drug patent expirations by year for AVYCAZ
Drug Prices for AVYCAZ

See drug prices for AVYCAZ

DrugPatentWatch® Estimated Generic Entry Opportunity Date for AVYCAZ
Generic Entry Date for AVYCAZ*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;IV (INFUSION)

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AVYCAZ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
Michigan State UniversityPhase 1
University of Southern CaliforniaPhase 4

See all AVYCAZ clinical trials

US Patents and Regulatory Information for AVYCAZ

AVYCAZ is protected by nine US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of AVYCAZ is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting AVYCAZ

Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM

Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM

Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BACTERIAL INFECTIONS

Heterocyclic compounds as inhibitors of beta-lactamases
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

FDA Regulatory Exclusivity protecting AVYCAZ

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Allergan AVYCAZ avibactam sodium; ceftazidime POWDER;INTRAVENOUS 206494-001 Feb 25, 2015 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for AVYCAZ

When does loss-of-exclusivity occur for AVYCAZ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 6972
Estimated Expiration: See Plans and Pricing

Australia

Patent: 12270051
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2013032415
Estimated Expiration: See Plans and Pricing

Canada

Patent: 80403
Estimated Expiration: See Plans and Pricing

China

Patent: 3649051
Estimated Expiration: See Plans and Pricing

Patent: 5294690
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 21005
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 96615
Estimated Expiration: See Plans and Pricing

Israel

Patent: 9815
Estimated Expiration: See Plans and Pricing

Japan

Patent: 23800
Estimated Expiration: See Plans and Pricing

Patent: 42462
Estimated Expiration: See Plans and Pricing

Patent: 14517027
Estimated Expiration: See Plans and Pricing

Patent: 17036307
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 5730
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 1020
Estimated Expiration: See Plans and Pricing

Patent: 13014114
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 10091
Estimated Expiration: See Plans and Pricing

Patent: 14101244
Estimated Expiration: See Plans and Pricing

Patent: 17102358
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 5289
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2143660
Estimated Expiration: See Plans and Pricing

Patent: 140040748
Estimated Expiration: See Plans and Pricing

Spain

Patent: 60404
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 65706
Estimated Expiration: See Plans and Pricing

Patent: 1317238
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AVYCAZ around the world.

Country Patent Number Title Estimated Expiration
Hong Kong 1244484 藥物化合物NXL104的多晶型形式和假多晶型形式 (POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104) See Plans and Pricing
South Korea 101817811 See Plans and Pricing
European Patent Office 1307457 COMPOSES AZABICYCLIQUES, LEUR PREPARATION ET LEUR UTILISATION COMME MEDICAMENTS , NOTAMMENT COMME ANTI-BACTERIENS (AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS) See Plans and Pricing
Australia 2001279905 See Plans and Pricing
Eurasian Patent Organization 004920 АЗАБИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, В ЧАСТНОСТИ В КАЧЕСТВЕ АНТИБАКТЕРИАЛЬНЫХ СРЕДСТВ (AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS) See Plans and Pricing
Austria 484281 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AVYCAZ

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1480644 SPC/GB17/004 United Kingdom See Plans and Pricing PRODUCT NAME: COMBINATION OF CEFTAZIDIME, OR A SALT THEREOF, AND AVIBACTAM, OR A SALT THEREOF; REGISTERED: UK EU/1/16/1109/001 20160628
1480644 C20160041 00213 Estonia See Plans and Pricing PRODUCT NAME: TSEFTASIDIIM/AVIBAKTAAM;REG NO/DATE: EU/1/16/1109 28.06.2016
1480644 629 Finland See Plans and Pricing
1480644 C01480644/01 Switzerland See Plans and Pricing PRODUCT NAME: AVIBACTAM + CEFTAZIDIM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66890 05.06.2019
1480644 2016/056 Ireland See Plans and Pricing PRODUCT NAME: A COMBINATION OF CEFTAZIDIME OR A SALT THEREOF, AND AVIBACTAM OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
1480644 16C1019 France See Plans and Pricing PRODUCT NAME: ASSOCIATION OU MELANGE PHARMACEUTIQUE RENFERMANT EN TANT QU'INGREDIENTS ACTIFS:(1) LA CEFTAZIDIME OU UN DES SES SELS ET (2) L'AVIBACTAM OU UN DE SES SELS; REGISTRATION NO/DATE: EU/1/16/1109 20160628
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Boehringer Ingelheim
Moodys
AstraZeneca
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.